Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEXTNANO

Financiado

NEXT GENERATION NANOPARTICLE-BASED ANTIBACTERIAL TREATMENT FOR INFECTED WOUNDS

Every 5th person with diabetes develops chronic wounds that are frequently infected by bacteria. In 15−27 % cases bacterial wound infection leads to the gangrene that requires an amputation of the leg. 10 mln of amputations occur... ver más

31/05/2023

NANORDICA MEDICAL...

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

NANORDICA MEDICAL OU No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-31

HORIZON-EIE-2021-SCALEUP-01-03: Women TechEU ExpectedOutcome:

Innovación

Cerrada hace 3 años

0% 100% 100%

1 Participantes

NANORDICA MEDICAL OU

75.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-115204RB-I00 BIOSENSORES BASADOS EN NANOCANALES Y NANOPARTICULAS PARA EL... 198K€ Cerrado

PRE2020-093041 RECUBRIMIENTOS DE HIDROGEL QUE CONTIENEN NANOPARTICULAS ANTI... 99K€ Cerrado

BES-2016-076682 Managing Chronicity and infectious diseases through nanomedi... 93K€ Cerrado

BioCaPHeal Flame-made calcium phosphate nanoparticles for biological dr... 207K€ Cerrado

NANO-PROTECT Antimicrobial nano-coatings for hospital textiles to prevent... 165K€ Cerrado

PTQ2020-011076 Sensores basados en nanopartículas de oro integrados en disp... 110K€ Cerrado

Duración del proyecto: 12 meses Fecha Inicio: 2022-05-16
Fecha Fin: 2023-05-31

Líder del proyecto

NANORDICA MEDICAL OU No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 75K€

Descripción del proyecto Every 5th person with diabetes develops chronic wounds that are frequently infected by bacteria. In 15−27 % cases bacterial wound infection leads to the gangrene that requires an amputation of the leg. 10 mln of amputations occur annually, showing that existing wound infection management treatments are inefficient. NEXTNANO aims to commercialize a new antibacterial nanotechology developed by our scientists and medical doctors to reduce the number of infection-related amputations by 20%. We showed in animals studies that our first product produced on the basis of this technology, an antibacterial wound dressing, is 8x times better than the current commercial best. Women TechEU grant would support the transition of our technology from the research and development stage to the commercialization stage. For that we have 4 Objectives: 1) To upgrade the commercialization strategy of our company; 2) To conduct the clinical assessment of our first product, antibacterial wound dressing; 3) To establish the quality management system (QMS) in our company and 4) To train participants. The main project results will be the improved commercialization strategy (including new contacts with the stakeholders), collaboration with the EU key opinion leaders and established QMS that will greatly increase the connectivity and competitiveness of our women-led deep-tech startup within innovation ecosystems of the EU. This will lead to more inclusive and gender equal innovation ecosystem in EU, since Estonia is one of the EU inclusiveness target countries and has one of the EU's highest inequalities between the salaries and top positions of women and men according to Eurostat. Not least, NEXTNANO will result in significant impacts: environmental (decreased use of antibiotics), societal (20% less amputations) and economical (10 mln eur revenue by 2026 and new high value-added jobs for 15 persons such as scientists, medical doctors, engineers and sales managers).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores